Busulfan Dosing for Bone Marrow Transplant

RS
MD
Overseen ByMeghan Donnelly, MPH
Age: < 65
Sex: Any
Trial Phase: Phase 1
Sponsor: Children's Hospital of Philadelphia
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The goal of this pilot study is to determine if scaling the first busulfan dose to Body Surface Area (BSA) in children with a BSA ≥0.5 m2 and using a BSA-banded dosing table for infants (BSA \<0.5 m2) increases the fraction of patients achieving a therapeutic drug exposure after the first dose.

Are You a Good Fit for This Trial?

This trial is for children who need a bone marrow transplant and will be receiving busulfan. It includes both infants (with smaller body size) and older children, as long as their body surface area can be measured.

Inclusion Criteria

My body surface area is at least 0.5 square meters.
My diagnosis may be either non-cancerous or cancerous.
I am 21 years old or younger.
See 3 more

Exclusion Criteria

I stopped taking phenytoin at least 21 days ago.
I have stopped taking deferasirox at least 7 days before joining the study.
I am not taking medicines that affect how my body clears busulfan.
See 3 more

What Are the Treatments Tested in This Trial?

Interventions

  • Busulfan

Trial Overview

The study is testing if adjusting the first dose of busulfan based on each child's body size helps more kids reach the right drug level after one dose. Different dosing methods are used for infants versus bigger children.

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Group I: Group BExperimental Treatment1 Intervention
Group II: Group AExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Children's Hospital of Philadelphia

Lead Sponsor

Trials
749
Recruited
11,400,000+

Alex's Lemonade Stand Foundation

Industry Sponsor

Trials
9
Recruited
1,500+